The NHS will not offer a drug that gives patients with advanced breast cancer a last hope because it is too expensive.
Women with HER2-positive breast cancer, which has spread to other parts of their body and has not responded to initial treatment, can see their lives extended by around six months by Kadcyla.
However, the National Institute for Health and Care Excellence (Nice) has ruled that at around £90,000 per patient, the drug is too expensive to recommend for widespread use in the health service.
The NHS financial watchdog criticised Roche, who manufactures the drug, for not discounting the treatment further.
Roche said that is had offered to cut the price of the drug and will be appealing Nice's decision.
More top news
Scientists have discovered the world's deepest fish with wing-like fins and an eel-like tail during research in the depths of the Pacific.
The tranquil district of Hart has been crowned as the place with the best quality of life in the UK for the fourth year in a row.
Britain's immigration system is in 'critical condition' according to the chair of the Home Affairs Select Committee.